



## Module 3 journal club

Dr Gareth Parkes

*Date: Monday 8 August 2022*

*Time: 18:00–19:00 CEST*

The purpose of this session is to develop your critical appraisal skills and literature awareness through interrogation and in-depth analyses of recent medical literature with your peers. The session will equip you with the skills needed to translate latest research into clinical practice and improve patient care in IBD.

To ensure you gain the most out of the journal club and can actively participate in discussions, please read the two papers using the links provided on the following pages, and consider the questions provided in advance.

As a reminder, this session **will not** be recorded for on-demand viewing. If you are unable to attend, please let us know in advance.

If you have any questions in the meantime or are experiencing any issues, please email us at [IBDTrainingAcademy@qlpg.com](mailto:IBDTrainingAcademy@qlpg.com).



## Paper 1

### Unmet medical needs in ulcerative colitis: an expert group consensus

Danese S, et al. *Dig Dis* 2019;37:266–283

Download available [here](#)

**Q1** What were the aims of this paper?

**Q2** What methodologies were used, and do they raise any questions for you?

**Q3** What do you think are the most important messages of the paper?

**Q4** Do you think the paper was clearly written with a logical structure?

**Q5** What are the limitations of this paper?

**Q6** What impact might the conclusions have on how you approach clinical practice?



## Paper 2

### Acceptance and commitment therapy reduces psychological stress in patients with inflammatory bowel diseases

Wynne B, et al. *Gastroenterology* 2019;156:935–945

Download available [here](#)

**Q1** Which specific questions does this study address?

**Q2** Was the paper clearly written? Was it well structured with a logical flow of information?

**Q3** What do you think about the study design? What are the limitations?

**Q4** How generalisable are the results? Are they statistically significant?

**Q5** How would you improve the study?

**Q6** How might the conclusions be applied to your own clinical practice?



This programme is organised and funded by Galapagos. This programme will contain mention of JYSELECA▼ (filgotinib) as part of a fair and balanced discussion about treatment options for IBD.

## **Prescribing and adverse event reporting information**

### Great Britain

JYSELECA 100 mg available [here](#)

JYSELECA 200 mg available [here](#)

### Ireland

JYSELECA 100 mg and 200 mg available [here](#)

### Belgium

JYSELECA 100 mg and 200 mg available [here](#)